[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"semaglutide\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:semaglutide":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,81,106,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100613918","impact-of-semaglutide-ozempicwegovy-on-heart-and-muscle-mass-100613918",false,"NCT07272837","Impact of Semaglutide (Ozempic\u002FWegovy®) on Heart and Muscle Mass","GLP-1 Receptor Agonist-Induced Loss and Impairment of Muscle Mass - Evaluation of Response","GLIMMER","Inclusion Criteria:\n\n* Adults 18-80 years of age\n* Starting semaglutide for type 2 diabetes or weight loss\n* Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)\n\nExclusion Criteria:\n\n* Current use of semaglutide for more than 2 weeks\n* Major recent heart issues or other severe health conditions\n* Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)\n* Dependence on a mobility aid (unable to participate in exercise MRI)","ALL","18 Years","80 Years",{"count":21,"type":22},50,"ESTIMATED","OBSERVATIONAL","The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.\n\nThis study involves (3) in-person study visits. At each visit, participants will be asked to:\n\n* Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.\n* Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.\n* Complete questionnaires related to demographics, health information, physical activity, and nutrition.\n* Have a blood sample collected from a vein in your arm.\n* Have your blood levels assessed through three finger pricks.\n* Complete three days of food records.",[26,27,28,29,30],"Type 2 Diabetes","Obesity","Semaglutide","GLP-1","Diabetes",[28,26,30,27,32,33,34,35,36,29,37,38],"Body Composition","Muscle Mass","Skeletal Muscle Mass","Cardiac Muscle Mass","GLP-1 Receptor Agonist","MRI","Magnetic Resonance Imaging","RECRUITING","2026-04-15",{"date":42,"type":43},"2026-04-20","ACTUAL",{"date":45,"type":22},"2026-04-14",{"date":47,"type":22},"2028-04-30",{"name":49,"class":50},"University of Alberta","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":51},"100613880","phase-4-the-impact-of-semaglutide-compared-to-energy-restriction-on-type-2-diabetes-100613880","NCT07272343","The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes","A Study on the Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Combined With Metabolic-associated Fatty Liver Disease and Its Molecular Mechanisms","Inclusion Criteria:\n\n1. Age 18-75 years;\n2. BMI≥25 kg\u002Fm²;\n3. Diagnosed as type 2 diabetes mellitus patients according to the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)\";\n4. HbA1c≤8.5%;\n5. Duration of diabetes ≤3 months, and no use of antihyperglycemic drugs;\n6. Willing to participate in this study, and after full informed consent, agrees to strictly follow the treatment plan and promises to attend follow-up visits on time, and signs the informed consent form.\n\nExclusion Criteria:\n\n1. BMI \\\u003C 25 kg\u002Fm²;\n2. Age \\\u003C 18 years, or \\> 75 years;\n3. History of type 1 diabetes, acute pancreatitis, or diabetes secondary to pancreatectomy;\n4. History of bariatric surgery or planned bariatric surgery, or currently attempting weight loss within the past 3 months, or use of weight-loss medications within the past 3 months;\n5. Use of GLP-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, or other related drugs within the past 3 months;\n6. Pregnant or breastfeeding women, or those planning to conceive during the study period;\n7. Patients with severe diseases of important organ systems, such as severe cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, renal insufficiency, hematologic diseases, neurological diseases, or malignancies;\n8. Personal or family history of medullary thyroid carcinoma;\n9. Patients with severe mental disorders or communication barriers that prevent accurate understanding of the study content and compliance with the trial procedures.","75 Years",{"count":61,"type":22},100,"INTERVENTIONAL",[64],"PHASE4","To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.",[67,28,68],"Type 2 Diabetes Mellitus (T2DM)","Caloric Restriction",[70,71,68],"Type 2 Diabetes Mellitus","semaglutide","2026-03-31",{"date":74,"type":43},"2026-04-02",{"date":76,"type":43},"2023-02-10",{"date":78,"type":22},"2026-07-01",{"name":80,"class":50},"Second Affiliated Hospital of Nanchang University",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":18,"enrollmentInfo":88,"targetDuration":4,"studyType":62,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":51},"100587920","phase-3-early-re-initiation-of-semaglutide-post-sleeve-gastrectomy-in-youth-100587920","NCT06934655","Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth","Inclusion Criteria:\n\n* ages 12 to 18 years\n* Tanner stage 3 or higher\n* severe obesity (defined as a BMI greater than 35 kg\u002Fm2 or BMI ≥140% of the 95th percentile)\n* currently undergoing primary surgical weight loss through the pediatric bariatric surgery pathway at Children's Hospital Los Angeles\n* be willing to have blood collected before and after surgical procedure at defined points\n* be willing to have clinical data entered into a prospective database; 8) presence of a consenting caregiver\n* be taking semaglutide 2.4 mg weekly as part of their routine medical care prior to surgery as part of their obesity treatment program, apart from any planned surgical procedure.\n\nExclusion Criteria:\n\n* have a previous diagnosis of type 1 diabetes\n* taking any medications known to influence body composition or prevent weight loss or promote weight gain (e.g. prednisone)\n* have been diagnosed with syndromes or diseases that may influence the postoperative course (e.g., Cushing syndrome, Down syndrome, Prader Willi Syndrome)\n* have significant comorbid medical conditions necessitating frequent hospitalization that may require interruption of medications and\u002For that would make early re-initiation of semaglutide unsafe due to the other medical comorbidities\n* refuse to comply with eligibility criteria.","12 Years",{"count":89,"type":22},150,[91],"PHASE3","This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care for 24 months. Primary, secondary, and tertiary outcomes will be assessed at multiple time points: 1-month, day of surgery, and 1-, 3-, 6-, 9-, 12-, 18-, and 24-months postoperatively. We hypothesize that early re-initiation of semaglutide will be safe, well-tolerated, and lead to greater improvements in obesity, cardiometabolic risk, and eating behaviors.",[94,95,28],"Pediatric Obesity","Metabolic and Bariatric Surgery","NOT_YET_RECRUITING","2026-03-16",{"date":99,"type":43},"2026-03-17",{"date":101,"type":22},"2026-06-01",{"date":103,"type":22},"2033-11-01",{"name":105,"class":50},"Children's Hospital Los Angeles",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":62,"phases":116,"briefSummary":117,"conditions":118,"keywords":127,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":51},"100585948","phase-3-semaglutide-treatment-in-type-1-diabetes-100585948","NCT06909006","Semaglutide Treatment in Type 1 Diabetes","Obesity and Semaglutide in Type 1 Diabetes Therapy: A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial","OBES1TY","Inclusion Criteria:\n\n* Type 1 Diabetes for more than 3 years\n* BMI ≥ 30 or ≥ 27 and atleast one comorbidity (hypertension, hypercholesterolemia, microalbuminuria, ischemic heart disease, history of stroke, atherosclerosis or arthrosis\n\nExclusion Criteria:\n\n* Treated with GLP1-RAs within last 6 months\n* Known intolerance for semaglutide\n* Other forms of diabetes\n* Pregnant or nursing women\n* Fertile women not using chemical (hormonal) or mechanical (spiral) contraceptives\n* Liver disease with elevated plasma alanine aminotransferase (ALT) \\> five times and plasma aspartate aminotransferase (AST) \\> five times the upper limit of normal (measured at visit 0 with the possibility of one repeat analysis within a week, and the last measured value as being conclusive)\n* Acute or chronic pancreatitis\n* Cancer, unless in complete remission for \\> 5 years or unless basocellular carcinomas\n* History of thyroid adenoma or carcinoma\n* Alcohol\u002Fdrug abuse\n* Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable for study participation\n* Receipt of an investigational drug within 30 days prior to visit 0 \u002F Simultaneous participation in any other clinical intervention trial",{"count":115,"type":22},122,[91],"The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.",[119,120,121,122,28,123,124,125,126],"Obesity in Diabetes","Obesity\u002FTherapy","Type 1 Diabetes Mellitus (T1DM)","Insulin Sensitivity\u002FResistance","Lipidomics","Metabolomics","Weight Loss","Glycemic Control for Diabetes Mellitus",[28,27,128,129,130,131,132,133,134,135],"Type 1 Diabetes","Obese Type 1 Diabetics","Insulin sensitivity","Insulin resistance","Weight loss","GLP1-RA","GLP1","Wegovy","2025-08-04",{"date":138,"type":43},"2025-08-08",{"date":140,"type":22},"2025-10",{"date":142,"type":22},"2028-06",{"name":144,"class":50},"Nordsjaellands Hospital",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":51},"100581898","response-to-semaglutide-in-non-diabetic-obese-patients-with-varying-degrees-of-insulin-resistance-100581898","NCT06856291","Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance","Treatment Response to Incretin Mimetics in Non-diabetic Obese Patients With and Without Insulin Resistance (TRIM-IR)","TRIM-IR","Inclusion Criteria:\n\n1. Age between 18 and 60 years\n2. BMI 30 - 40 kg\u002Fm2\n\n   a. Participants must meet the eligibility criteria for coverage under the KVG (Federal Health Insurance Act) and the Specialties List, which include a weight-related comorbidity (arterial hypertension, dyslipidemia) for participants with a BMI of 30- 35 kg\u002Fm2\n3. Planned therapy with semaglutide as a weight loss intervention\n4. No known presence of a diabetic state\n5. Ability to understand and sign a Patient Information and Consent Form\n\nExclusion Criteria:\n\n1. Pregnancy or active breast feeding\n\n   1. Therapy with semaglutide is not approved for use during pregnancy or while breastfeeding, as its safety and efficacy in these conditions have not been established.\n   2. Pregnancy is an exclusion criterion for the planned investigations to avoid placing pregnant individuals under unnecessary physical or psychological stress that could pose risks to both the individual and the fetus.\n2. Medication and\u002For pathologies that prevent the safe execution of the fat tissue biopsies (e.g. allergy towards local anesthetics, disorders of coagulation, treatment with anticoagulants)\n3. Medical conditions that prevent examinations and testing (e.g. epilepsia, symptomatic cardiovascular disease)\n4. History of or planned bariatric surgery\n5. HbA1c ≥ 6.5% as measured by the central laboratory at screening\n6. Fasting plasma-glucose \\>7.0 mmol\u002Fl\n7. History of type 1 or type 2 diabetes mellitus\n8. Treatment with glucose-lowering agent(s) (e.g. Metformin) within 90 days before screening\n9. Treatment with a GLP-1 (glucagon like peptide 1) receptor agonist within 180 days before screening\n10. A self-reported change in body weight \\>5% within 90 days before screening\n11. Active malignancy (\\\u003C2a since remission)\n12. Treatment with any medication for the indication of obesity within the past 90 days before screening\n13. Uncontrolled thyroid disease, defined as thyroid stimulating hormone (TSH) \\> 10 mIU\u002FL or \\\u003C 0.4 mIU\u002FL as measured by the central laboratory at screening","60 Years",{"count":155,"type":22},40,"Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile. As the most commonly prescribed drug in this class, semaglutide is effective in both diabetic and non-diabetic individuals. However, treatment responses vary significantly, with non-diabetic individuals typically experiencing better weight loss outcomes. Despite this, up to 10% of non-diabetic individuals show little or no response to treatment, and the reasons for this variability remain unclear.\n\nThe TRIM-IR study aims to investigate the role of insulin resistance (IR) in weight loss outcomes among non-diabetic obese individuals receiving semaglutide. This single-center, observational study will assess the impact of IR on weight loss, body composition, and adipose tissue function during the first 16 weeks of semaglutide therapy. The study will also explore molecular markers of adipose tissue dysfunction, focusing on the transition from dysfunctional to healthy adipose tissue.\n\nThe investigators hypothesize, that individuals with lower IR will experience greater weight loss than those with higher IR, and that the glucose infusion rate (GIR) during hyperinsulinemic euglycemic clamp testing will correlate with weight loss variability. Secondary objectives include comparing changes in fat and lean mass, reductions in visceral fat, and improvements in adipose tissue function before and after 16 weeks of treatment. Exploratory analyses will assess adipocyte subpopulations and their response to insulin sensitivity changes.\n\nA total of 40 participants, equally distributed by gender, will be enrolled to ensure statistical power for detecting clinically relevant differences. The study aims to optimize semaglutide use for personalized obesity treatment and provide insights into the relationship between obesity, insulin resistance, and adipose tissue plasticity, with implications for improving obesity management and cardiovascular health outcomes.",[158,159,122,28],"Obesity and Obesity-related Medical Conditions","Obesity and Overweight",[161,162,71,163,164,165,166,167,168],"Insulin Resistance","incretin mimetics","weight loss","adipose tissue function","obesity","hyperinsulinemic euglycemic clamp","obesity management","insulin sensitivity","2025-03-24",{"date":171,"type":43},"2025-03-25",{"date":173,"type":43},"2025-03-15",{"date":175,"type":22},"2026-08-31",{"name":177,"class":50},"ETH Zurich"]